for a phase three trial of a lung cancer treatment.
While the drug compared well to a competitor on one endpoint, the data for overall survival was "not mature" and pointed toward to the results being not statistically significant, AstraZeneca said in a press release. The trial will continue, according to the company.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: MarketWatch - 🏆 3. / 97 Lire la suite »
Recession will take shine off stocks' AI-fueled rally in H2: HSBCUS stocks face a painful rest of 2023 with a recession set to take the shine off the AI-fueled rally, HSBC says
La source: BusinessInsider - 🏆 729. / 51 Lire la suite »